From: PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells
Cell lines (SAHA: Veliparib)
CI values (IC50)
LNCap (1:20)
0.86
C4–2 (1:20)
0.95
VCaP (1:20)
0.90
CWR22Rv1 (1:20)
0.85
PC-3 (1:20)
0.74
DU145 (1:20)
RWPE-1 (1:20)
1.05